浩欧博: 江苏浩欧博生物医药股份有限公司关于出售土地使用权、厂房建筑物的公告

Core Viewpoint - Jiangsu Haooubo Biopharmaceutical Co., Ltd. plans to sell land use rights and factory buildings to Suzhou Xinliancheng Software Co., Ltd. for a total price of 19.52 million yuan, aiming to optimize asset structure and maintain reasonable asset allocation [1][2][11] Transaction Overview - The transaction was approved at the 24th meeting of the third board of directors on August 1, 2025, and does not require shareholder approval [2][4] - The sale involves land use rights and factory buildings located at No. 218 Xinghu Street, Suzhou Industrial Park, with a total transfer price of 19.52 million yuan, including tax [2][3] - The transaction does not constitute a related party transaction or a major asset restructuring [1][4] Buyer Information - The buyer, Suzhou Xinliancheng Software Co., Ltd., was established on October 19, 2016, with a registered capital of 10 million yuan, primarily engaged in software development and sales [4][5] Asset Details - The asset being sold has a book value of 11,070,583.08 yuan as of June 30, 2025, with a historical cost of 17,339,100 yuan [6][5] - The asset is free from any encumbrances, litigation, or other restrictions on transfer [5][6] Valuation and Pricing - The asset was appraised at 19.01 million yuan as of June 19, 2025, resulting in a valuation increase of 71.75% compared to its book value [6][8] - The final transaction price of 19.52 million yuan was determined through negotiation, reflecting a fair and reasonable pricing principle [8][7] Payment and Delivery Terms - The payment structure includes a 95% payment within 30 working days after the contract becomes effective, with the remaining 5% due within 3 days after obtaining the property rights certificate [9][10] - The risk of loss or damage to the property will transfer to the buyer upon delivery or completion of the property rights registration [9][10] Impact on Company - The sale is intended to optimize the company's asset structure and will not affect its normal operations or harm the interests of shareholders, particularly minority shareholders [11]